MedTrace Logo

CHED - Congenital Hereditary Endothelial Dystrophy: New Paradigm Shift in Therapy Using Topical Eye Drops

NCT04843839 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2021-04-14

No results posted yet for this study

Summary

CHED- Congenital Endothelial Endothelial Dystrophy is a condition that causes corneal cloudiness.

Since, currently only surgery is being done to cure this condition, we are taking up the research of using topical eye drops for this condition which is a very simple and easy method.

Also, there are no significant side effects to this treatment.

Conditions

  • Congenital Hereditary Endothelial Dystrophy of Cornea

Interventions

DRUG

Nepafenac 0.1% Oph Susp

Nepafenac 0.1% eye drops - Allergan : Dosage- 1 drop QID for 6 months

DRUG

Refresh Tears 0.5% Lubricant Eye Drops

Refresh Tears 0.5% w/v eye drops - Allergan : Dose- 1 drop QID for 6 months

Sponsors & Collaborators

  • Allergan

    collaborator INDUSTRY

  • L.V. Prasad Eye Institute

    lead OTHER

Principal Investigators

  • Muralidhar Ramappa, MS · L.V. Prasad Eye Institute

  • Neet Y Mehta, MBBS · L.V. Prasad Eye Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Max Age
6 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-15
Primary Completion
2022-12-15
Completion
2022-12-15

Countries

  • India

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04843839 on ClinicalTrials.gov